Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Miriam B Garcia, DO
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objective: • To determine the safety and tolerability of the combination of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or Lymphoma (LBL). Secondary Objectives: * To conduct a preliminary assessment of efficacy in adolescent and young adult patients treated with this combination based on: * Best overall response (BOR), including complete remission (CR), CR with partial hematological recovery (CRh), CR with incomplete blood count recovery (Cri), morphologic free state (MLFS), partial remission (PR), stable disease (SD), and progressive disease (PD) * Time-to-event outcomes: overall survival (OS), event-free survival (EFS), and duration of response (DOR) * Composite remission rate (CRc), defined as CR, CRh, CRi, and MLFS
Age
12–30
Sex
ALL
Healthy volunteers
Not accepted
